Trial · NCT07892287
Effect of Neurofeedback and TMS
NCT07892287, Not applicable, Not yet recruiting, Massachusetts General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Neurofeedback and TMS. Trials, record NCT07892287. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07892287
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Neurofeedback and TMS
- NCT number
- NCT07892287
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Depression - Major Depressive Disorder
- Interventions
- Repetitive Transcranial Magnetic Stimulation, Alpha-down EEG Neurofeedback
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility and Tolerability of NFB and rTMS Interventions | From enrollment to the end of treatment after 6 days. | The primary outcome measure will be measured through session completion rates, adverse event frequency, and participant satisfaction. |
| Secondary | Change in Depression Symptom Severity as Measured by the Hamilton Depression Rating Scale | From enrollment to the end of treatment after 6 days. | Changes in depressive symptom severity will be assessed by comparing baseline and post-treatment scores of the Hamilton Depression Rating Scale (HAM-D). The HAM-D measures the severity of depression based on observations made by trained personnel during a clinical interview. Scores range from 0 to 52, with higher scores representing greater depression symptom severity. |
| Secondary | Changes in Rumination | From enrollment to the end of treatment after 6 days. | Changes in rumination will be assessed by comparing baseline and post-treatment scores of the Ruminative Responses Scale (RRS). The Ruminative Responses Scale measures an individual's tendency to repetitively think about negative emotions and engage in self-critical thinking. Scores range from 22 to 88, with higher scores indicating greater levels of rumination. |
| Secondary | Change in Emotion Regulation | From enrollment to the end of treatment after 6 days. | Changes in emotional regulation will be assessed through the baseline and post-treatment scores of the Emotion Regulation Questionnaire (ERQ). The Emotion Regulation Questionnaire measures cognitive reappraisal and expressive suppression. Scores range from 10 to 70, with higher scores indicating frequent application of emotion regulation strategies. |
| Secondary | Changes in Attentional Control | From enrollment to the end of treatment after 6 days. | Changes in attentional control will be measured through comparing baseline and post-treatment Emotional Stroop task scores. Emotional Stroop measures attentional bias towards emotional stimuli. |
| Secondary | Changes in Alpha-Band EEG Power and Connectivity | From enrollment to the end of treatment after 6 days. | Alpha-band EEG activity will be assessed during EEG recordings. Changes in 8-12 Hz alpha-band power and connectivity from baseline to post-treatment will be measured as neurophysiological change. |
| Secondary | Change in Depression Symptom Severity as Measured by the Beck Depression Inventory | From enrollment to the end of treatment after 6 days. | Changes in depression symptom severity will be assessed by comparing baseline and post-treatment Beck Depression Inventory (BDI) scores. The Beck Depression Inventory is a self-report questionnaire designed to assess the severity of depressive symptoms. Scores range from 0 to 63, with higher scores indicating greater depression symptom severity. |
| Other | Changes in Alcohol Use Behavior | From enrollment to the end of treatment after 6 days. | Changes in alcohol use behavior will be characterized by comparing baseline and post-treatment scores of the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C). The Alcohol Use Disorders Identification Test-Consumption measures the frequency and quantity of drinking. Scores range from 0 to 12, with higher scores indicating hazardous drinking behaviors. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers32
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Emotional Stroop Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07892287
GET https://conductscience.org/api/trials/v1/NCT07892287/papers?page=2